Q-omics provides the consensus-scored MZF1 profile across patient tissues and cancer cell-line models. MZF1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MZF1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, MZF1 RNA expression shows 19,892 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, COAD, and UVM as cancer lineages where MZF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MZF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MZF1 survival associations across molecular data types. MZF1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MZF1 RNA expression–survival associations across cancer types. High MZF1 expression shows unfavorable associations in KIRC, LIHC, LGG and ACC, but favorable associations in BLCA and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MZF1 RNA expression.
This table summarizes MZF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MZF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MZF1 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LIHC, READ and CHOL. The COAD box plot shows higher MZF1 RNA expression in tumor versus normal tissue (log2 FC = +1.398, t-test p < 0.001).
This table shows molecular features associated with MZF1 in patient tissues and cancer cell lines. In patient samples, MZF1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MZF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
